The Effect of Probiotics on the Clinical Outcomes and Gut Microenvironment in Patients With Fatty Liver

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-08-30

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fatty liver has been associated with high risk of progression to inflammation of the liver, liver cirrhosis (hardening of the liver), and eventually can lead to liver cancer. So far, the treatment for this condition involves controlling the cholesterol level in the body by practicing low fat diet and daily exercise. However, recently there has been evidence that alteration of the normal population of various types of bacteria that lives in the intestines may contributes to the development of fatty liver.

Probiotics is a dietary supplement containing live bacteria that is formulated to change the composition and population of the bacteria in the intestines. It is postulated that by taking specifically formulated probiotics, the alteration of the intestinal bacteria may lead to improvement of the fatty liver, leading to better daily liver function.

In this 6-month study, investigators would like to investigate the effectiveness of the probiotics in improving the liver function and in the treatment of the fatty liver. It will compare the fatty liver of patients who took the probiotics supplements compared to those who did not took it and see if there is any improvement.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Evaluate the Beneficial Effect of Probiotics on NAFLD Patients and the Role of Gut Microbiota Modulation

NCT05402449

Non-Alcoholic Fatty Liver Disease

COMPLETED NA

Probiotics and Its Associated Factors on Aflatoxin Biomarkers

NCT03882294

Aflatoxicosis

COMPLETED NA

Effects of Probiotics (P. Pentosaceus, L. Lactis or L. Helveticus) in NASH

NCT04555434

Non-Alcoholic Fatty Liver Disease

UNKNOWN NA

Efficacy and Safety of a Probiotic Composition as Adjunct in MAFL Management

NCT04823676

Non Alcoholic Fatty Liver

COMPLETED NA

Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease

NCT01501162

Alcoholic Liver Disease

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Non-alcoholic fatty liver disease (NAFLD) is one of the common causes of chronic liver disease nowadays. NAFLD is considered as the hepatic manifestation of metabolic syndrome. In Malaysia, the prevalence of metabolic disorders such as diabetes mellitus, obesity and dyslipidemia are increasing with time. Despite the disease burden, treatments for NAFLD are currently limited due to the ongoing evolving theory of its pathogenesis.

One of the proposed mechanisms is via gut-liver axis (GLA), whereby the role of gut microbiota has been implicated. Two main components of GLA are gut microbiota and gut barrier. A change in gut microbiota composition will predispose to gut barrier dysfunction, which subsequently leads to bacterial by-products translocation into the portal circulation. Eventually, these by-products reach the liver and trigger the cascades of hepatic inflammation, leading to fatty liver and its disease progression.

The aim of this study is to investigate the role of probiotics in modulating the gut microenvironment - namely gut microbiota composition, gut barrier function and local gut inflammation, as well as its effect on the clinical outcomes in NAFLD patients.

Investigators propose a randomised, double-blind, placebo-controlled trial of 6-month duration. Investigators aim to recruit 48 NALFD patients, with either treated with probiotics or placebo. Small intestinal microbiota will be determined by 16S-rRNA sequencing and immunoreactivity of zona occludens-1 (tight junction protein in the gut barrier) and cytokines mRNA level will be measured. The degree of liver steatosis and stiffness will be assessed by using transient elastography and biochemical blood tests. All these variables will be determined pre- and post-intervention with probiotics/placebo.

This study will provide a valuable knowledge on the role of probiotics as the gut microenvironment modulator and strengthen the hypothesis of GLA involvement in the NAFLD development. Hence, probiotics can be strongly considered as one of the treatment options for non-alcoholic fatty liver disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Alcoholic Fatty Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomised, double-blind, placebo-controlled trial

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

Patients will be given Lactobacillus \& Bifidobacterium containing probiotics \[Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg\], to be taken 1 sachet twice daily for 6 months.

Group Type ACTIVE_COMPARATOR

(Microbial cell preparation) Probiotics

Intervention Type DIETARY_SUPPLEMENT

Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg)

Group B

Patients will be given placebo sachet (exactly the same packaging as active comparator) to be taken 1 sachet twice daily for 6 months.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo sachet with no microbial cell preparation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

(Microbial cell preparation) Probiotics

Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg)

Intervention Type DIETARY_SUPPLEMENT

Placebo

Placebo sachet with no microbial cell preparation

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Hexbio

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 and above 2. Diagnosis of NAFLD is confirmed by the presence of fatty liver detected by abdominal ultrasound and controlled attenuation parameter (CAP) score from FibroScan® of \>263 3. Raised ALT level (above upper limit of normal): \> 35IU/L for males and \> 25 IU/L for females

Exclusion Criteria

1. Evidence of other chronic liver diseases (as determined by clinical and standard investigations) - e.g. Hepatitis B, C infections, autoimmune hepatic disorders.
2. Evidence of acute disorders that affecting the liver - e.g. drug induced liver injury, non-Hepatitis B, C viral infection.
3. Biliary disease.
4. Liver cancer - primary hepatocellular carcinoma or liver metastasis.
5. Evidence of liver cirrhosis.
6. Alcohol intake \> 20g/day for males and \>10g/day for females.
7. Use of steatogenic medications within the past one months - e.g. systemic steroids, methotrexate.
8. History of bariatric surgery
9. Intake of antibiotics and/or probiotic and proton pump inhibitor within one month before the start of the study or during the study period.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No